https://sputnikglobe.com/20211007/sputnik-v-developer-to-begin-trials-of-combo-flucovid-19-vaccine-in-late-2022-1089733306.html
Sputnik V Developer to Begin Trials of Combo Flu/COVID-19 Vaccine in Late 2022
Sputnik V Developer to Begin Trials of Combo Flu/COVID-19 Vaccine in Late 2022
Sputnik International
MOSCOW (Sputnik) - Russia's Gamaleya Research Center will begin clinical trials of a combined influenza and coronavirus vaccine at the end of 2022, Director... 07.10.2021, Sputnik International
2021-10-07T08:22+0000
2021-10-07T08:22+0000
2021-10-07T08:22+0000
russia
vaccine
covid-19
https://cdn1.img.sputnikglobe.com/img/07e5/05/09/1082841328_0:141:3141:1907_1920x0_80_0_0_5efa5e2271812813545254c55ab15e01.jpg
A hybrid vaccine against rotaviruses was taken as the basis for the future drug. In parallel, research is underway to develop a vaccine effective against various variants of the coronavirus.Other Russian research centers, namely Vector, are also developing a combined vaccine against influenza and COVID-19.
russia
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
russia, vaccine, covid-19
russia, vaccine, covid-19
Sputnik V Developer to Begin Trials of Combo Flu/COVID-19 Vaccine in Late 2022
MOSCOW (Sputnik) - Russia's Gamaleya Research Center will begin clinical trials of a combined influenza and coronavirus vaccine at the end of 2022, Director Alexander Gintsburg said on Thursday.
A hybrid vaccine against rotaviruses was taken as the basis for the future drug. In parallel, research is underway to develop a vaccine effective against various variants of the coronavirus.
"The technological platform for this has already been created, but clinical trials have not yet begun. If everything goes well with this platform, this technology works, then we will move on to a more complex option - combining influenza hemagglutinin antigens and, accordingly, coronavirus S-proteins in one vaccine. The clinical trials of the new drug will begin at the end of next year," Gintsburg told the Izvestia newspaper.
Other Russian research centers, namely Vector, are also developing a combined vaccine against influenza and COVID-19.
